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Infections with rapidly growing mycobacteria are rare and most often seen in immunocompro-
mised patients. We herein present the case of a 69-year-old man with a T-cell lymphoma
treated by chemotherapy and mogamulizumab with a 6-month history of febrile episodes and
subcutaneous nodules in both arms and arthritis of metacarpophalangeal joints. Blood cultures
and DNA sequencing results demonstrated the growth of Mycobacterium chelonae. The patient
was successfully treated with clarithromycin, moxifloxacin, and tobramycin, but died shortly
after due to lymphoma progression.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Infections with rapidly growing mycobacteria (RGM) are rare
and most often seen in patients with a compromised
immune system. We herein present the case of a 69-year-
old man with a disseminated Mycobacterium chelonaeinfection after he had undergone treatment for a peripheral
T-cell lymphoma (PTCL).Case report
A 69-year-old man presented with a 6-month history of feb-
rile episodes with signs of lethargy, cough, and shortness of
breath, but with moderate recovery after antibiotic treat-
ment. Furthermore, he noticed red-purple nodules on both
upper arms (Fig. 1) and a painful swelling of both third-cell lym-
Figure 1 Red-purple nodules on the upper arm.
Figure 2 Swollen third metacarpophalangeal joint.
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His medical history was remarkable for a PTCL (PTCL not
otherwise specified, with aberrant CD20 expression), Stage
III, International Prognostic Index Score 3, for which he
was initially treated with CHOP chemotherapy (cyclophos-
phamide, doxorubicin, vincristine, and prednisolone) and
rituximab, which had a partial response. Disease progression
occurred after 12 months and he received second-line treat-
ment with R-PECC (rituximab with lomustine, etoposide,
chlorambucil, and prednisolone). After partial remission,
his treatment was interrupted for toxicity reasons. Unfortu-
nately, within several months, his disease progressed with
growing cervical lymphadenopathy with biopsy-proven
recurrence of T-cell lymphoma. He was included in a Phase
II trial with mogamulizumab [anti-CC chemokine receptor 4
(anti-CCR4) antibody]. Although his disease stabilized,
treatment had to be stopped after 7 months according to
the trial protocol due to Grade III thrombocytopenia. After
cessation of medication, cervical lymphadenopathy reap-
peared with episodes of fever and night sweats, suggestive
of recurrent disease for which palliative treatment with
prednisolone was given.Please cite this article in press as: van der Wekken L et al., Disseminat
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ature of 37.8 C and showed five subcutaneous purple nod-
ules on the dorsal side of his right arm and a larger plate-
formed nodus and two smaller nodules on his left arm. Both
third metacarpophalangeal joints showed redness, swelling,
and were warm and painful on palpation.
Initial laboratory findings demonstrated a slight increase
in C-reactive protein levels (46 mg/L; normal range: 0–
10 mg/L). In addition, complete blood count test results
indicated a normocytic anemia [hemoglobin level of
8.1 mmol/L (normal range: 8.5–11 mmol/L) and mean cor-
puscular volume of 95 fL (normal range: 80–100 fL)], throm-
bocytopenia (80  109/L; normal range: 150–400  109/L),
normal leukocyte count (9.8  109/L; normal range: 4.0–
10.0  109/L), and an elevated lactate dehydrogenase level
of 486 U/L (normal range: 0–250 U/L).
A positron emission tomography–computed tomography
(PET–CT) showed uptake of fluorodeoxyglucose (FDG) in
the upper and middle lobes of the lung and in multiple sub-
cutaneous nodules in both arms. An enlarged FDG-positive
spleen and inguinal and parailiac lymph nodes were
observed; however, these lymph nodes were unchanged in
size compared with an abdominal CT scan 1 year earlier.
In the synovial fluid aspirated from his left third metacar-
pophalangeal joint, acid-fast bacilli were found by Ziehl–
Neelsen staining. There was not enough material for further
cultures. His blood cultures grew M. chelonae, which was
in vitro sensitive for clarithromycin and moxifloxacin.
Two nodules were excised from his left arm, from which
M. chelonae DNA was identified by LIPA gene sequencing.
Pathologic examination of the nodules showed a panniculitis
with granulomatosis, in which no T-cell lymphoma could be
demonstrated. The patient was initially treated with oral
clarithromycin and moxifloxacin, and intravenous tobramy-
cin. After 1 month, the nodules diminished in size and he
reported an improved general well-being. Because of renal
insufficiency, tobramycin was discontinued after 2 months
of treatment, after which the nodules and fever did not
reoccur.
Two months after discharge, the patient was readmitted
because of shortness of breath. A PET–CT was repeated and
a decrease in subcutaneous nodules was seen. However,
increases in lymphadenopathy, splenomegaly, and bilateral
pulmonary infiltrates were visible. Lymph node biopsy fol-
lowed in which no mycobacterial DNA was detectable.
Pathological examination of the lymph node revealed
relapse of the T-cell lymphoma.
By this time, the patient’s clinical condition deterio-
rated. No further treatment options were available and
the patient was discharged home, with palliative care. He
died at home within several days.Discussion
Mycobacteria other than Mycobacterium tuberculosis and
Mycobacterium leprae are called ‘‘atypical” or ‘‘nontuber-
culous mycobacteria” (NTM) and can be divided into slow-
growing mycobacteria and RGM. Mycobacterium avium
complex, Mycobacterium kansasii, and Mycobacterium
xenopi are the best known slow-growing mycobacteria,ed Mycobacterium chelonae infection in a patient with T-cell lym-
l Ther (2016), http://dx.doi.org/10.1016/j.hemonc.2016.04.004
Disseminated Mycobacterium chelonae infection 3whereas Mycobacterium fortuitum, Mycobacterium absces-
sus, and M. chelonae are well-known RGM. They are envi-
ronmental organisms isolated from water, soil, and
aerosols. They can be cultured in regular culture media,
although they need a lower optimal growth temperature
(around 30 C) [1].
The exact incidence and prevalence of NTM-related dis-
ease are unclear, because reporting cases is not mandatory.
Second, due to their environmental existence, isolates from
humans cannot be used to determine the incidence of NTM,
because an isolation of an NTM does not necessarily indicate
clinical disease [2].
Infection with RGM can lead to several clinical syn-
dromes. First of all, pulmonary disease due to RGM has been
reported. Pulmonary disease due to RGM is predominantly
due to M. abscessus (80% of cases). Although pulmonary dis-
ease is associated with underlying lung disease, this is not
the case in all patients. Most patients have a prolonged time
from onset of symptoms to diagnosis [3]. Moreover, infec-
tion with RGM can present, although rare, with dissemi-
nated disease. It is most often seen in patients with
severe immunosuppression and hematological malignancies.
The disseminated form of the disease presents with multiple
subcutaneous nodules or abscesses [4]. Finally, RGM infec-
tions can be caused by inoculation, surgery, or prosthetic
implantation, resulting in multiple, recurrent abscesses
and wound infections [5,6].
One of the risk factors for developing a disseminated
infection with RGM is immunosuppression. Although
immunocompetent patients have also been reported with
disseminated disease, the majority of patients have an obvi-
ous underlying condition that compromises immunity.
Patients with renal transplant, collagen vascular disease,
or hematological malignancies are more likely to develop
a disseminated RGM infection, especially when cell-
mediated immunity is impaired by corticosteroids or cyto-
static agents [7,8].
Our patient was treated with several immunosuppressing
medicines such as prednisolone, rituximab, and moga-
mulizumab (anti-CCR4). CCR4 is highly expressed by regula-
tory T cells (Tregs) and T-helper cells, inducing homing.
CCR4 is expressed in tumor cells in approximately 30–65%
of the patients with PTCL. Mogamulizumab is a defucosy-
lated, humanized, IgG1 monoclonal antibody that binds to
CCR4, with enhanced antibody-dependent cellular
cytotoxicity.
The mechanism of action of mogamulizumab is twofold:
it enhances antibody-dependent cellular cytotoxicity and
depletes CCR4+ Tregs, potentially evoking antitumor
immune responses by autologous effector cells. A Phase II
trial in PTCL and cutaneous T-cell lymphoma patients
reported an overall response rate of 35% in those who
relapsed after their last systemic therapy [9], leading to
its approval in Japan.
The exact mechanism of the increased risk of developing
an infection with RGM in immunocompromised hosts is
unknown. Most research has been conducted in the host
defense against M. tuberculosis, which shows a prominent
role for interleukin-12 (IL-12), interferon-c (IFN-c), and
tumor necrosis factor-a. These cytokines are responsible
for promoting a Type 1 T helper cell (Th-1) response,Please cite this article in press as: van der Wekken L et al., Disseminat
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CCR4 is normally associated with a Th-2 immune response,
although recent research showed a comparable Th-1 and
Th-2 granulomatous response after the introduction of
Mycobacterium bovis antigen-coated agarose beads in the
lungs of mice. CD4+ T cells secreting IL-4 and IFN-c also
expressed transcripts for CCR4 and responded to CCR4
ligands [11].
In our patient, the total CD4 count during moga-
mulizumab therapy dropped from 390  1000/mL to
220  1000/mL (normal count: 404–1612  1000/mL). Fur-
thermore, it could be hypothesized that the blockage of
CCR4 by mogamulizumab can ultimately lead to a blockage
of the Th-11 immune response needed to form granulomas
and overcome an infection with mycobacteria, thus increas-
ing the risk of developing a disseminated infection with
RGM, such as M. chelonae.
After the patient stopped treatment with moga-
mulizumab, he presented with recurrent cervical lym-
phadenopathy, which was considered at that moment to
be a progression of his T-cell lymphoma. However, no biopsy
was done to confirm the diagnosis. Possibly, at that time,
there was no disease progression after all, but rather a first
presentation of an M. chelonae infection with cervical
lymphadenitis and fever, which temporarily responded to
prednisolone and antibiotic treatment but disseminated
due to inadequate treatment.
Conclusion
In this case report, we presented a patient with a history of
febrile episodes with lung involvement and subcutaneous
nodules and arthritis, caused by a disseminated M. chelonae
infection. To the best of our knowledge, this is the first case
to describe an infection with a rapid-growing mycobac-
terium in a patient with a T-cell lymphoma after treatment
with a CCR4 antibody. In patients with a comprised cell-
mediated immunity and infectious episodes with negative
blood culture, one should consider an infection with RGM.
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